Covid-19 living Data

Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

A table with the general characteristics and risk of bias assessment for all RCTs identified.
A synthesis with forest plots and summary of findings table/evidence profile including phase 2-3 trials. For the vaccine (dose and schedule) evaluated in phase 2-3 trials, results available for the same vaccine (dose and schedule) in phase 1-2 trial will also be included in the synthesis.

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Inactivated virus

Non replicating viral vector

ChAdOx1 vs MenACWY (University of Oxford/AstraZeneca )

RNA based vaccine

BNT162b2 vs Placebo (BioNTech/Fosun Pharma/Pfizer )

mRNA-1273 vs Placebo (ModernaTX)

Last update: 22/01/2021

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias	Full description
		Intervention 1	Intervention 2
NCT04324606; ISRCTN15281137; EudraCT 2020-001072-15 University of Oxford/AstraZeneca Folegatti PM (COV001), Lancet, 2020 Full text Barrett JR, Nature medicine, 2020 Full text Ewer KJ, Nature medicine, 2020 Full text Commentary Commentary	Non replicating viral vector	ChAdOx1	MenACWY	RCT Phase 1/2	Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK	N=1077	Low Details	Full description
NCT04368988 Novavax Keech C., N Engl J Med, 2020 Full text Commentary	Non replicating viral vector	2 dose 25mcg NVX-D0/21	Placebo	RCT Phase 1	Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia.	N=134	Some concerns Details	Full description
		2 dose 5mcg NVX/M1-D0/21	Placebo
		2 dose 25mcg NVX/M1-D0/21	Placebo
		1 dose 25mcg NVX/M1+Placebo-D0/21	Placebo
NCT04436276 Janssen Pharmaceutical Companies Sadoff J,MedRxiv,2020 Full text Commentary	Non replicating viral vector	Ad26.COV2.S 5x10^10vp	Placebo	RCT Phase 1	Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US	N=785	High Details	Full description
	Non replicating viral vector	Ad26.COV2.S 1x10^11vp	Placebo	RCT Phase 1		N=785	High Details	Full description
NCT04400838 University of Oxford/AstraZeneca Voysey M (COV002), Lancet, 2020 Full text Commentary	Non replicating viral vector	ChAdOx1 LD/SD	1/2 doses MenACWY	RCT Phase 2/3	Healthy adults in 18 centers in the UK	N=7548	Some concerns Details	Full description
	Non replicating viral vector	ChAdOx1 SD/SD	1/2 doses MenACWY	RCT Phase 2/3	Healthy adults in 18 centers in the UK	N=7548	Some concerns Details	Full description
ISRCTN89951424 University of Oxford/AstraZeneca Voysey M (COV003), Lancet, 2020 Full text Commentary	Non replicating viral vector	ChAdOx1 SD/SD	MenACWY/saline	RCT Phase 3	Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil	N=4088	Some concerns Details	Full description
NCT04444674 University of Oxford/AstraZeneca Voysey M (COV005), Lancet, 2020 Full text Commentary	Non replicating viral vector	ChAdOx1 std 2 doses	Saline	RCT Phase 1/2	Healthy adults from four studies in multiple centres in Brazil, South Africa, and the UK	N=2013	Details	Full description
NCT04341389 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F, The Lancet, 2020 Full text Commentary Commentary	Non replicating viral vector	Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp	Placebo	RCT Phase 2	Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China.	N=508	Some concerns Details	Full description
		Adenovirus type-5-vectored COVID-19 5×10¹° vp	Placebo
		Adenovirus type-5-vectored COVID-19 1 × 10¹¹ vp	Adenovirus type-5-vectored COVID-19 5×10¹° vp

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.